Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
P21 vs Selank
An educational, source-based comparison of P21 and Selank — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic peptide derived from cerebrolysin. Research suggests it promotes synaptic plasticity by enhancing BDNF expression and inhibiting prolyl endopeptidase, an enzyme involved in neurodegenerative processes.
- Synaptic plasticity and memory
- Neuroprotection in Alzheimer's models
- Cognitive recovery after brain injury
- • Experimental; limited human data available.
- • Not FDA-approved.
A synthetic analog of the immunomodulatory peptide tuftsin. Research suggests it modulates GABAergic and serotonergic systems and influences expression of brain-derived neurotrophic factor without the sedation or dependence profile of benzodiazepines.
- Generalized anxiety models
- BDNF expression
- Immune modulation
- Memory and learning in rodent models
- • Not FDA-approved.
- • Most studies are Russian clinical literature.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| P21 | P21 promotes synaptic plasticity in aged rodents | Neuroscience Letters | 2015 | Enhanced dendritic spine density and BDNF expression in hippocampal tissue. |
| Selank | Selank in generalized anxiety disorder | Zhurnal Nevrologii i Psikhiatrii | 2008 | Comparable anxiolytic effect to medazepam without sedation or withdrawal. |
Side-effect & safety grid
- Experimental; limited human data available.
- Not FDA-approved.
- Not FDA-approved.
- Most studies are Russian clinical literature.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
P21 vs Selank — Key differences
- Class: P21 is classified as Nootropic · Neuroprotection, while Selank is Anxiolytic · Nootropic.
- Primary research focus: P21 — synaptic plasticity and memory; Selank — generalized anxiety models.
- Tag: Cognition · Neuroprotection vs Calm · Cognition.
Selank Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Generalized anxiety research (human pilot studies) | Adults with generalized anxiety disorder in Russian clinical studies | Intranasal solution (0.15%) | Commonly cited as 250–300 mcg/day divided across nostrils | 14 days in most reported study courses | Published mainly in Russian-language literature; Selank is not FDA-approved and has no Western regulatory dossier. |
| Cognitive and attention research | Healthy adult volunteers | Intranasal | Single doses in the 100–400 mcg range reported | Acute, single-session testing | Outcome measures were attention and short-term memory tasks; sample sizes were small. |
| Preclinical anxiolytic models | Rodent | Intraperitoneal or intranasal | Typically 100–300 mcg/kg | Acute to 7–14 days | Effects attributed to modulation of GABA-A expression, enkephalinase inhibition, and BDNF signaling. |
Selank — Frequently Asked Questions
What is a commonly referenced Selank dose in research?+
Published Russian clinical work most often describes an intranasal 0.15% solution delivering roughly 250–300 mcg per day over a two-week course. No FDA-approved dose exists, and these figures describe study protocols rather than a recommendation.
How is Selank administered in studies?+
Almost all human studies use an intranasal spray or drops, because the peptide is degraded quickly in the gastrointestinal tract. Preclinical models also use intraperitoneal injection.
How long does Selank stay active?+
Selank is a heptapeptide (a tuftsin analogue stabilized with a Pro-Gly-Pro tail), and plasma half-life is reported in minutes. Study designs therefore rely on repeated daily intranasal dosing rather than long-acting exposure.
Is Selank the same as Semax?+
No. Both are Russian-developed regulatory peptides with a Pro-Gly-Pro motif, but Semax is an ACTH(4-10) analogue studied more for attention, neuroprotection and BDNF, while Selank derives from tuftsin and is studied more for anxiety and immune modulation.
Is Selank approved anywhere?+
Selank is registered as a medicine in Russia. It is not approved by the FDA or EMA, is not available through licensed U.S. pharmacies, and material sold online is unverified for identity and purity.
What safety signals appear in Selank research?+
Reported studies describe mild, transient effects such as nasal irritation, headache, or drowsiness, with no serious adverse events in short courses. Long-term human safety data do not exist, which is the main limitation of the evidence base.